Show simple item record

dc.creatorMureithi, Marianne W.
dc.creatorPoole, Danielle.
dc.creatorNaranbhai, Vivek.
dc.creatorReddy, Shabashini.
dc.creatorMkhwanazi, Nompumelelo Prudence.
dc.creatorSibeko, Sengeziwe.
dc.creatorWerner, Lise.
dc.creatorAbdool Karim, Quarraisha.
dc.creatorAbdool Karim, Salim Safurdeen.
dc.creatorNdung'u, Thumbi.
dc.creatorAltfeld, Marcus.
dc.date.accessioned2012-11-24T07:09:54Z
dc.date.available2012-11-24T07:09:54Z
dc.date.created2011
dc.date.issued2011
dc.identifier.citationMureithi, M.W. et al. 2012. Preservation HIV-1–specific IFNg+ CD4+ T-Cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr. 60 (2), pp. 124-127.en
dc.identifier.issn1525-4135
dc.identifier.urihttp://dx.doi.org/10.1097/QAI.0b013e31824f53a9en
dc.identifier.urihttp://hdl.handle.net/10413/7997
dc.description.abstractAbstract: The Centre for the AIDS Program of Research in South Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition in women using a vaginal microbicide containing tenofovir. A better understanding of the consequences of antiretroviral-containing microbicides for immune responses in individuals with intercurrent HIV-1 infection is needed for future trials combining the use of microbicides with HIV-1 vaccines. Investigation of immune responses in women who acquired HIV-1 although using tenofovir gel showed significantly higher (P = 0.01) Gag-specific IFNγ+ CD4+ T-cell responses. The use of tenofovir-containing gel around the time of infection can modulate HIV-1 immunity, and these immunological changes need to be considered in future trials combining vaccines and microbicides.en
dc.language.isoenen
dc.publisherLippincott Williams & Wilkins.en
dc.subjectAIDS vaccines.en
dc.subjectAIDS (Disease)--Vaccination.en
dc.subjectHIV infections--Immunology.en
dc.subjectClinical trials.en
dc.subject.otherTenofovir.en
dc.subject.otherVaginal microbicides.en
dc.subject.otherHIV-1-specific CD4+ T-cell help.en
dc.titlePreservation HIV-1–specific IFNg+ CD4+ T-Cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.en
dc.typePeer reviewed journal articleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record